Log in to search using one of your social media accounts:

 

Spiriva (Tiotropium Bromide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2017 Category: Drugs & Pharmacology Source Type: news

Spiriva Respimat (Tiotropium Bromide Inhalation Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2017 Category: Drugs & Pharmacology Source Type: news

Tiotropium for Mild to Moderate COPD Tiotropium for Mild to Moderate COPD
Is it time to consider using a daily long-acting bronchodilator like tiotropium for early-stage COPD?Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news

Tiotropium Effective in Mild to Moderate COPD
Daily inhaled dose tied to improvements in FEV1 compared to placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 7, 2017 Category: Respiratory Medicine Tags: Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Long-acting inhaler may help in early stage COPD
The inhaler medication Spiriva may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 7, 2017 Category: Consumer Health News Source Type: news

Daily Tiotropium Confers Some Benefits in Mild-to-Moderate COPD (FREE)
By the Editors Tiotropium is associated with benefits in stage 1 and 2 chronic obstructive pulmonary disease, according to an industry-funded study in the New England Journal of … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 7, 2017 Category: Primary Care Source Type: news

Tiotropium Boosts Lung Function in Early COPD (CME/CE)
(MedPage Today) -- Higher FEV1 at 24 months in Chinese study, but long-term impact unclear (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - September 6, 2017 Category: Respiratory Medicine Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 6, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Did Congress just kill medical device innovation? The Medical Device User Fee Amendments bill that Congress passed this year is more than an FDA fees hike for device companies; it could inhibit innovation, says Michael Drues, a...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Long-Acting Inhaler May Help in Early Stage COPD, Too
WEDNESDAY, Sept. 6, 2017 -- The inhaler medication Spiriva (tiotropium bromide) may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. Researchers found that the drug helped patients preserve more... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2017 Category: General Medicine Source Type: news

Pulmatrix licenses inhaled COPD drug to Vectura
Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura. The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix licenses inhaled COPD drug to Vectura appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - August 22, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news

Tiotropium Add-on Tx Improved Lung Function in Kids with Asthma
(MedPage Today) -- Disease phenotype had no impact on treatment (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - May 24, 2017 Category: Allergy & Immunology Source Type: news

Spiriva Respimat improves breathing in asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 23, 2017 Category: Research Source Type: news

Single Inhaler Triple Therapy Effective for COPD Single Inhaler Triple Therapy Effective for COPD
A single inhaler triple therapy provides clinical benefits superior to those of the muscarinic antagonist tiotropium alone in patients with symptomatic chronic obstructive pulmonary disease (COPD), according to the TRINITY trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 20, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide
Glenmark Pharmaceuticals said today that the FDA approved its Investigational New Drug application for a Phase II study of its nebulized tiotropium bromide. The Mahwah, N.J.-based company plans to enroll 155 patients with mild to moderate chronic obstructive pulmonary disease and evaluate its GSP 304 formulation as a daily maintenance treatment for bronchospasm. Get the full story at our sister site, Drug Delivery Business News. The post Glenmark wins FDA nod for Phase II study of nebulized tiotropium bromide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Food & Drug Administration (FDA) Respiratory Wall Street Beat Glenmark Pharmaceuticals Source Type: news

FDA Expands Approval of SPIRIVA(R) RESPIMAT(R) (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., Feb. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance t... Biopharmaceuticals, FDA Boehringer Ingelheim, SPIRIVA, RESPIMAT, tiotropium bromide, Asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2017 Category: Pharmaceuticals Source Type: news

FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., February 16, 2017 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in people age... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 16, 2017 Category: Drugs & Pharmacology Source Type: news

Tiotropium Respimat vs Tiotropium HandiHaler in COPD Tiotropium Respimat vs Tiotropium HandiHaler in COPD
These inhalers provide two options for the delivery of tiotropium in patients with COPD. Find out how they compare.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2016 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Olodaterol/tiotropium cost  effective for COPD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news

Adding Tiotropium to Teen Asthma Therapy Adding Tiotropium to Teen Asthma Therapy
Once-daily tiotropium improved lung function and was safe and well tolerated when added to inhaled corticosteroid therapy, but would a LABA work just as well?Medscape Pulmonary Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 14, 2016 Category: Allergy & Immunology Tags: Pulmonary Medicine Viewpoint Source Type: news

More Respimat data from Boehringer
Boehringer Ingelheim on Tuesday touted results from the Phase III CanoTinA asthma trial, which showed that adding tiotropium Respimat to maintenance asthma therapy in kids ages 6-11 significantly improves lung function compared to placebo. The results were presented Tuesday at the European Respiratory Society International Congress 2016 in London. This comes 1 day after results from another clinical trial showed the company’s drug-device Stiolto Respimat aids patients with chronic obstructive pulmonary disease walk for longer periods of time without experiencing shortness breath. The Can...
Source: Mass Device - September 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Boehringer Ingelheim Pharmaceuticals Source Type: news

Tiotropium Respimat < sup > ® < /sup > improved lung function in children with asthma
Tiotropium Respimat® improved lung function in children with asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 6, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Boehringer Ingelheim touts Stiolto Respimat data Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary ...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath. When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along with exercise, their exercise capacity increased by 45.8% compared to those receiving a placebo. The Physacto trial is a part of the Tovito Phase III clinical trial, investigating the efficacy of Respimat as a maintenance therapy for COPD. &l...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Respiratory Boehringer Ingelheim Pharmaceuticals Source Type: news

Tiotropium RESPIMAT ® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 5, 2016 Category: Research Source Type: news

New Data: STIOLTO(R) RESPIMAT(R) (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
RIDGEFIELD, Conn., Sept. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COP... Biopharmaceuticals, Devices, Drug Delivery Boehringer Ingelheim, STIOLTO RESPIMAT, tiotropium, olodaterol, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 5, 2016 Category: Pharmaceuticals Source Type: news

New Data: STIOLTO ® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news

SPIRIVA < sup > ® < /sup > RESPIMAT < sup > ® < /sup > Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
SPIRIVA ® RESPIMAT ® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New Analyses: Adding SPIRIVA < sup > ® < /sup > Respimat < sup > ® < /sup > Effective for Uncontrolled Asthma
New Analyses: Adding SPIRIVA ® Respimat ® Effective for Uncontrolled Asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat < sup > ® < /sup > significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment
ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat ® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS † treatment (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat < sup > ® < /sup > effective across asthma severities "
" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat ® effective across asthma severities " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA < sup > ® < /sup > in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III results: tiotropium* Respimat < sup > ® < /sup > is effective in symptomatic asthma patients irrespective of their allergic status
Phase III results: tiotropium* Respimat ® is effective in symptomatic asthma patients irrespective of their allergic status (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III results: tiotropium* Respimat < sup > ® < /sup > effective in symptomatic asthma patients despite at least ICS †/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
Phase III results: tiotropium* Respimat ® effective in symptomatic asthma patients despite at least ICS †/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat < sup > ® < /sup > to the treatment of asthma in adults aged 18 years and over
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat ® to the treatment of asthma in adults aged 18 years and over (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Additional results from post-hoc analysis underline effectiveness of SPIRIVA < sup > ® < /sup >
Additional results from post-hoc analysis underline effectiveness of SPIRIVA ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva < sup > ® < /sup > ) alone
ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva ® ) alone (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New large-scale study to investigate effect of tiotropium + olodaterol Respimat < sup > ® < /sup > on exacerbations in COPD
New large-scale study to investigate effect of tiotropium + olodaterol Respimat ® on exacerbations in COPD (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

" European Respiratory Society International Congress 2014 TONADO < sup > ™ < /sup > - further lung function and quality of life benefits with tiotropium + olodaterol Respimat < sup > ® < /sup > FDC* in COPD "
" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat ® FDC* in COPD " (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: new indication for Spiriva < sup > ® < /sup > (tiotropium) Respimat < sup > ® < /sup > * in the EU may offer millions of adults a significant advance in asthma care
Asthma: new indication for Spiriva ® (tiotropium) Respimat ® * in the EU may offer millions of adults a significant advance in asthma care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New data show benefit of tiotropium/olodaterol Respimat < sup > ® < /sup > from the start of COPD maintenance therapy
New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: U.S. FDA approves new indication for SPIRIVA < sup > ® < /sup > Respimat < sup > ® < /sup >
Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat ® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva < sup > ® < /sup > Respimat < sup > ® < /sup > in asthma
Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat ® in asthma (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

​Pulmatrix shares climb as generic Spiriva hits goals in early-stage trial
An inhalable drug for chronic obstructive pulmonary disease, or COPD, being developed by Lexington biotech Pulmatrix and drug giant Mylan, met its goals in an early-stage trial, potentially clearing the way to be marketed in Europe. The news boosted the stock price of the small local biotech by 10 percent this morning to $2.45 a share, giving the company a market value of $36 million. Pulmatrix (Nasdaq: PULM) has a method of delivering drugs using a dry powder it calls iSPERSE which it says is… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 19, 2016 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Stiolto Respimat (tiotropium bromide and olodaterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 24, 2016 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray
People living with chronic obstructive pulmonary disease (COPD) can earn rewards for tracking medication use and learning more about COPD (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 7, 2016 Category: Research Source Type: news

Tiotropium inhalation spray effective for asthma regardless of allergic status
LOS ANGELES – Once-daily tiotropium bromide inhalation spray as long-term, add-on maintenance therapy in patients with poorly controlled symptomatic asthma is similarly effective in both allergic and... (Source: Pediatric News)
Source: Pediatric News - May 1, 2016 Category: Journals (General) Source Type: news

Tiotropium inhalation spray effective for asthma regardless of allergic status
LOS ANGELES – Once-daily tiotropium bromide inhalation spray as long-term, add-on maintenance therapy in patients with poorly controlled symptomatic asthma is similarly effective in both allergic and... (Source: Family Practice News)
Source: Family Practice News - May 1, 2016 Category: Primary Care Source Type: news

Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy
• New post-hoc analysis shows routine eosinophil blood test could help identify the small minority   of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study benefited from addition of ICS on top of SPIRIVA®   HANDIHALER®‡ and a LABA§ with regards to exacerbation risk reduction • The data analysis, published in Lancet Respiratory Medicine, adds to current debate about appropriate   selection of patients for ICS treatment in chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 7, 2016 Category: Research Source Type: news

FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 28, 2016 Category: Research Source Type: news